News
Projects
Orgs
Project
Articles 52
Votes 0
FierceBiotech

Authors 9

Ben Adams
Helen Floersh
FierceBiotech
James Waldron
Max Bayer
Nick Paul Taylor
Darren Incorvaia
Conor Hale
Gabrielle Masson
Roche's oral SERD flunks phase 3 trial in 1st-line breast cancer, raising questions of mechanism's limits - Fierce Biotech
18d
Lilly buys Orna in $2.4B deal to enter in vivo CAR-T arena - Fierce Biotech
~2mo
NIH turmoil takes center stage as director acknowledges no vaccine-autism link - Fierce Biotech
~2mo
Sanofi abandons attempt to develop next-gen mRNA seasonal flu vaccine - Fierce Biotech
~2mo
AstraZeneca pens $630M pact to secure remaining rights to armored CAR-T from AbelZeta - Fierce Biotech
2mo
3 new venture funds collect nearly $1B for biotech in US, EU - Fierce Biotech
3mo
Baby KJ scientist launches personalized CRISPR therapy startup - Fierce Biotech
3mo
Alumis beams as pivotal data on Sotyktu rival drive stock surge - Fierce Biotech
3mo
Quanterix's blood test for Alzheimer's disease uncovers potentially treatable population in decades-long study - Fierce Biotech
3mo
Verge Genomics drops sole clinical candidate in return to AI drug discovery roots - Fierce Biotech
3mo
Intellia pauses phase 3 CRISPR trials after patient is hospitalized - Fierce Biotech
5mo
Celcuity's breast cancer combo hits goals, teeing up FDA filing - Fierce Biotech
8mo
Recursion lays off 20% of staff in wake of pipeline cutbacks - Fierce Biotech
10mo
JPM24: Lilly CEO David Ricks to biotechs: 'We're open for business' - FierceBiotech
~2y
JPM24, Day 2: GSK, Eli Lilly, Blueprint, SR One and more - FierceBiotech
~2y
Drug more effective on pain than gabapentin, minus side effects - FierceBiotech
>2y
Hepatitis B drug developers chart slow progress forward, just like hep C before it - FierceBiotech
>2y
Verve shows base editing works in humans in first clinical data—and is punished by investors - FierceBiotech
>2y
AstraZeneca's long-term GLP-1 play is weight management, not obesity, CEO says - FierceBiotech
>2y
CRISPR-Vertex gene editing 1st gets narrow review by FDA panel - FierceBiotech
>2y
Merck pays $4B for Daiichi ADCs in bet on post-Keytruda future - FierceBiotech
>2y
Beam lays off 20% of staff and culls CAR-T work to save cash - FierceBiotech
>2y
Akero's NASH miss drags a few peers down, spurring deja vu in long-challenging indication - FierceBiotech
>2y
FDA hopes to spur stimulant use disorder drug development - FierceBiotech
>2y
FDA's single-trial guidance calls for the good, bad and ugly data to support effectiveness - FierceBiotech
>2y